- FY 2023 financial and business results.
- FY 2024 financial and business outlook.
- Status of Company’s relocation to its new manufacturing facility.
- Update on Uncle Bud’s Health and Wellness
- Product expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products:
- Next Generation Skincare (with nano-retinol).
- Next Generation Nootropic (cognitive/memory enhancer).
- Best-in-Class Nanoemulsified Antioxidant Cocktail for both B2B and DTC sales.
- Placement of 1st Generation UltraShear benchtop equipment into multiple cannabis companies – for brand awareness of fast-acting (3-5 minutes) THC edible products.
Interested stakeholders may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website) approximately one day after the teleconference.
The teleconference will include a Company presentation followed by a Question & Answer period.
Date: | Time: |
To attend this teleconference, live by telephone, Dial: (888) 267-2918 (
For those unable to participate in the live teleconference, a Replay will be available after the call. The Replay link will be posted on the PBIO website after the call to allow stakeholders to download and listen to the Replay of the call.
About
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended
For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts | |
(T) 508-230-1828 | |
(T) 650-812-8121 |
Source:
2024 GlobeNewswire, Inc., source